Abstract Number: 1721 • 2018 ACR/ARHP Annual Meeting
Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study
Background/Purpose: Genetic and environmental factors play a significant role in SSc. African Americans are known for a higher SSc incidence, an earlier age of onset,…Abstract Number: 1733 • 2018 ACR/ARHP Annual Meeting
Should We Perform Exercise Echocardiogram As a Screening Test for Pulmonary Arterial Hypertension (PAH) for All Systemic Sclerosis (SSc) Patients?
Background/Purpose: Prevalence of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) is 8-12%, and 3-year survival rate is 47-56%. Rest echocardiogram is used to screen…Abstract Number: 2676 • 2017 ACR/ARHP Annual Meeting
Reduction of Dlco and FVC in Patients with GERD and Systemic Sclerosis
Background/Purpose: Esophageal involvement is common in Systemic Sclerosis (SSc). It is estimated to occur in 70-90% of patients. Esophageal motor dysfunction is characterized by hypotonia…Abstract Number: 2678 • 2017 ACR/ARHP Annual Meeting
Comparison of Scleroderma Associated Isolated Pulmonary Arterial Hypertension and Pulmonary Hypertension with Concomitant Interstitial Lung Disease
Background/Purpose: Relatively little data exist in the literature to characterize the differences between patients with scleroderma-associated isolated pulmonary arterial hypertension (SSc-PAH, WHO Group 1) and…Abstract Number: 2679 • 2017 ACR/ARHP Annual Meeting
Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Survival in scleroderma associated pulmonary arterial hypertension (SSc-PAH) is known to be significantly worse compared to that in idiopathic pulmonary arterial hypertension (iPAH). However,…Abstract Number: 2687 • 2017 ACR/ARHP Annual Meeting
Characteristic of Pulmonary Arterial Hypertension in Patients with Anti-U1RNP Antibody-Positive-Connective Tissue Diseases Is Determined By the Underlying Disease Rather Than Autoantibody Profile
Background/Purpose: Patients with connective tissue diseases (CTDs) positive for anti-U1RNP antibody (U1) is characterized by overlapping feature of systemic sclerosis (SSc), systemic lupus erythematosus (SLE),…Abstract Number: 2737 • 2017 ACR/ARHP Annual Meeting
Pulmonary Manifestations of Primary Systemic Vasculitides
Background/Purpose: Pulmonary involvement in systemic primary vasculitides is diverse and occurs with variable incidence depending on the type of vasculitis. This study aimed to describe…Abstract Number: 378 • 2017 ACR/ARHP Annual Meeting
Musculoskeletal Features in Copa Syndrome
Background/Purpose: COPA syndrome is a newly discovered primary immunodeficiency resulting in immune dysregulation showing autosomal dominant inheritance with incomplete penetrance. Its name is derived from…Abstract Number: 2980 • 2017 ACR/ARHP Annual Meeting
Chemokine CCL21 As a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose : Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles of chemokines CCL19/21 and their receptor…Abstract Number: 730 • 2017 ACR/ARHP Annual Meeting
The Association of Pulmonary Hypertension with Isolated Nucleolar Serum Autoantibodies in Systemic Sclerosis
Background/Purpose: Serum antibodies are used to identify SSc patients who may be at higher risk for SSc-PH. The Pulmonary Hypertension Assessment and Recognition of Outcomes…Abstract Number: 752 • 2017 ACR/ARHP Annual Meeting
Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution
TitleRole of the Six-Minute Walk Test in Systemic Sclerosis: five years evolution. Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading…Abstract Number: 944 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Background/Purpose: Anti-Th/To antibody is an autoantibody associated with systemic sclerosis (SSc), occurring in 5-10% of patients. To date, only relatively small case series have described…Abstract Number: 947 • 2017 ACR/ARHP Annual Meeting
Norway As a National Reference Population for Systemic Sclerosis; Preliminary Results from a Complete, Nationwide Cohort
Background/Purpose: To fully understand the impact of Systemic sclerosis (SSc) there is a need to complement existing multi-center registry data with novel, unbiased, high resolution…Abstract Number: 1276 • 2017 ACR/ARHP Annual Meeting
Nail Fold Capillary Changes Are Associated with Pulmonary, but Not with Cardiac Involvement in Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disease of unknown origin, characterised primarily by cutaneous rashes and symmetrical weakness of the proximal skeletal muscles.…Abstract Number: 1697 • 2017 ACR/ARHP Annual Meeting
Unique Characteristics of Scleroderma Among African Americans: A Population Based Study
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease categorized on the basis of skin involvement as either limited or diffuse cutaneous SSc, the latter…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »